Vedolizumab for extraintestinal manifestations in pediatric inflammatory bowel disease: Results from the VedoKids study

Extraintestinal manifestations (EIMs) manifest in 6%‐47% of patients with inflammatory bowel disease (IBD). Here, we characterize the course of EIMs in pediatric patients receiving vedolizumab included in the VedoKids cohort study. This was a subgroup analysis of the pediatric VedoKids cohort, a multicenter, prospective study of children (aged 0–18 years) with IBD treated with vedolizumab and followed through 54 weeks. EIMs were identified in 18/142 (12.6%) children at baseline; 56% of these cases were articular EIMs; the EIMs resolved in 89% within 18 months. Concomitant medications were administered in 72% of EIM cases, most of which were ongoing at the time of vedolizumab initiation. Of the 124 children without EIMs, five (4%) developed EIMs during follow up: three arthritis, two cutaneous manifestations. The presence of EIMs did not affect the durability of vedolizumab treatment. In conclusion, most EIMs in children with IBD resolved with vedolizumab treatment, but almost half received concomitant medications. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02862132. https://clinicaltrials.gov/study/NCT02862132?term=NCT02862132&rank=1 .